Johnson & Johnson Income from Continuous Operations 2012-2026 | JNJ
Johnson & Johnson annual/quarterly income from continuous operations history and growth rate from 2012 to 2026. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change
- Johnson & Johnson income from continuous operations for the quarter ending March 31, 2026 was $5.235B, a 52.4% decline year-over-year.
- Johnson & Johnson income from continuous operations for the twelve months ending March 31, 2026 was $21.040B, a 3.53% decline year-over-year.
- Johnson & Johnson annual income from continuous operations for 2025 was $26.804B, a 90.56% increase from 2024.
- Johnson & Johnson annual income from continuous operations for 2024 was $14.066B, a 5.55% increase from 2023.
- Johnson & Johnson annual income from continuous operations for 2023 was $13.326B, a 18.59% decline from 2022.
|
Johnson & Johnson Annual Income from Continuous Operations (Millions of US $) |
|
|---|---|
| 2025 | $26,804 |
| 2024 | $14,066 |
| 2023 | $13,326 |
| 2022 | $16,370 |
| 2021 | $17,801 |
| 2020 | $14,714 |
| 2019 | $15,119 |
| 2018 | $15,297 |
| 2017 | $1,300 |
| 2016 | $16,540 |
| 2015 | $15,409 |
| 2014 | $16,323 |
| 2013 | $13,831 |
| 2012 | $10,514 |
| 2011 | $9,672 |
|
Johnson & Johnson Quarterly Income from Continuous Operations (Millions of US $) |
|
|---|---|
| 2026-03-31 | $5,235 |
| 2025-12-31 | $5,116 |
| 2025-09-30 | $5,152 |
| 2025-06-30 | $5,537 |
| 2025-03-31 | $10,999 |
| 2024-12-31 | $3,431 |
| 2024-09-30 | $2,694 |
| 2024-06-30 | $4,686 |
| 2024-03-31 | $3,255 |
| 2023-12-31 | $4,132 |
| 2023-09-30 | $4,309 |
| 2023-06-30 | $5,376 |
| 2023-03-31 | $-491 |
| 2022-12-31 | $2,097 |
| 2022-09-30 | $4,310 |
| 2022-06-30 | $4,814 |
| 2022-03-31 | $5,149 |
| 2021-12-31 | $1,659 |
| 2021-09-30 | $3,667 |
| 2021-06-30 | $6,278 |
| 2021-03-31 | $6,197 |
| 2020-12-31 | $1,738 |
| 2020-09-30 | $3,554 |
| 2020-06-30 | $3,626 |
| 2020-03-31 | $5,796 |
| 2019-12-31 | $4,010 |
| 2019-09-30 | $1,753 |
| 2019-06-30 | $5,607 |
| 2019-03-31 | $3,749 |
| 2018-12-31 | $3,042 |
| 2018-09-30 | $3,934 |
| 2018-06-30 | $3,954 |
| 2018-03-31 | $4,367 |
| 2017-12-31 | $-10,713 |
| 2017-09-30 | $3,764 |
| 2017-06-30 | $3,827 |
| 2017-03-31 | $4,422 |
| 2016-12-31 | $3,814 |
| 2016-09-30 | $4,272 |
| 2016-06-30 | $3,997 |
| 2016-03-31 | $4,457 |
| 2015-12-31 | $3,215 |
| 2015-09-30 | $3,358 |
| 2015-06-30 | $4,516 |
| 2015-03-31 | $4,320 |
| 2014-12-31 | $2,521 |
| 2014-09-30 | $4,749 |
| 2014-06-30 | $4,326 |
| 2014-03-31 | $4,727 |
| 2013-12-31 | $3,519 |
| 2013-09-30 | $2,982 |
| 2013-06-30 | $3,833 |
| 2013-03-31 | $3,497 |
| 2012-12-31 | $2,567 |
| 2012-09-30 | $2,629 |
| 2012-06-30 | $1,408 |
| 2012-03-31 | $3,910 |
| 2011-12-31 | $218 |
| 2011-09-30 | $3,202 |
| 2011-06-30 | $2,776 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $574.358B | $94.193B |
| Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |